Drug intelligence / Profile preview

YYC506-T

Development stage: Unknown
Lead developer: Yooyoung Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

YYC506-T is a code name for a component of the fixed-dose combination drug YYC 506, which is being developed by Yooyoung Pharmaceutical for the treatment of dyslipidemias, including hyperlipidemia. The combination consists of two components, YYC506T and YYC506A. Clinical trials have evaluated the safety and pharmacokinetics of both components individually and in combination. The overall product (YYC-506) is classified as a small molecule drug and has reached Phase 3 clinical development for complex dyslipidemia where LDL-C is controlled but triglyceride (TG) and HDL-C levels are not adequately regulated by atorvastatin alone. Specific details about the mechanism of action or molecular targets for YYC506-T itself are not disclosed in public sources[1][2][3][6].

Beyond the preview

Go deeper on YYC506-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YYC506-T.

Explore the full profile